Plasma Derived Therapy Market Size to Surpass USD 33.75 Bn by 2030
According to the global Plasma Derived Therapy market size was estimated at USD 18.25 billion in 2021 and is expected to surpass around USD 33.75 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 7.07% during the forecast period 2022 to 2030
Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6947
Key Takeaways:
- North America region held 53% revenue share in 2021.
- Asia Pacific plasma derived therapy market is growing at a CAGR of 7.8% during the forecast period.
- By product, the immunoglobulin segment is growing at a CAGR of 7.3% between 2022 to 2030.
- Albumin segment is anticipated to grow at a CAGR of 7.7% during the forecast period.
- Idiopathic thrombocytopenic purpura segment size was estimated at around USD 610 million in 2021.
Demand for plasma-derived drugs rises as plasma antibodies, immunoglobulins, clotting factors, fibrinogens, and other plasma-derived medicinal compounds can be extracted from plasma that has a wide range of applications and advantages.
Plasma-derived medicinal products (PDMPs) are used in medical treatment and prevention to treat autoimmune disorders and bleeding emergencies. Hence, the sales of plasma-derived drugs are expected to spike.
In addition, the demand for plasma-derived drugs can be attributed to chronic conditions like hemophilia, congenital and acquired immunodeficiencies, etc., which can also be treated with the aid of plasma-derived drugs.
Furthermore, increasing regulatory approvals for plasma-derived medicines are expected to drive the sales of plasma derived drugs during the forecast period. For example, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, announced in January 2022 that the National Medical Products Administration (NMPA) of China granted BPL a license to market ALBUMINEX 25 percent product in China.
Higher sales of plasma derived drugs can be attributed to key market players' increased adoption of inorganic strategies, such as agreements and collaborations.
The rise in the prevalence of rare and chronic diseases creates a more lucrative opportunity for market manufacturers to enlarge their plasma derived drugs market share.
Immunoglobulin products, albumin products, clotting factors, and a few others are currently available in the plasma-derived drugs market that significantly aids in the treatment of various diseases, which in turn, scales up the sales of plasma derived drugs. The rising demand for plasma derived drugs is also due to the unique mechanism associated with each plasma-derived drug and its usage to achieve better clinical outcomes.
Report Scope of the Plasma Derived Therapy Market
Report Coverage |
Details |
Market Size in 2022 |
USD 19.54 Billion |
Market Size by 2030 |
USD 33.75 Billion |
Growth Rate from 2022 to 2030 |
CAGR of 7.07% |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Product, Application and Geography |
Companies Mentioned |
CSL Behring, Takeda Pharmaceutical Company Limited, BPL, ADMA Biologics, Biotest AG, Octapharma, Grifols, Kamada Pharmaceuticals, SK Plasma, SA, Kedrion, Pfizer |
Full Report is Ready | Quick Buy This Premium Report from Here@ https://www.novaoneadvisor.com/report/checkout/6947
What Factors are Shaping the Plasma-Derived Drugs Market Dynamics?
Demand for plasma derived drugs goes up as the cost of manufacturing plasma derived drugs is more than four times the cost of manufacturing other pharmaceuticals.
The business model for plasma-derived drugs is different than what is present in the pharmaceutical market. The clear-cut research process and drug discovery process is different; moreover, the industry requires a more vigorous approach to create a balance in the sales, thereby dwindling the sales of plasma derived drugs. Manufacturers of plasma-derived drugs spend the majority of their resources on manufacturing each drug, and the same is making them give second thoughts, which may result in lower plasma derived drugs market share.Sales of plasma derived drugs are lowered due to threats present in developing plasma-derived drugs.
Furthermore, threats of emerging pathogens greatly affect the production cost for each manufacturer in the plasma derived drugs market. The manufacturing of plasma-derived drugs takes a significant time, it could go from eight months to more than twelve months, and any shortcomings during the period can create serious consequences for the company affecting the market dynamics.
The same is considered as one of the factors adversely affecting the demand for plasma derived drugs as well as sales of plasma derived drugs during the forecast period.
The demand for plasma derived drugs is impacted by government policies that present to increase the number of blood banks. Plasma policies aim to make the availability, and accessibility of plasma to a greater extent, and such aim significantly influences the sales of plasma derived drugs. Demand for plasma derived drugs surges on account of moving the available adequate amount of plasma throughout different corners for better.
Segmental Insights
Product Insights
On the basis of product, the segment of immunoglobulin plasma has emerged as the fastest growing market as compared to its competitors. The increasing demand of this plasma derived component has attracted the potential consumers considerably. The huge number of chronic diseases that are treated with the help of this immunoglobulin plasma derived component has been a major factor which has helped the market to achieve a considerable position in the global economy and is expected to grow in a similar fashion during the future as well. The other products which are included under this category are albumin derived therapies and coagulation factor which are also showing a considerable growth over the period of time with increasing research and development performed by the key market players.
Application Insights
On the basis of application, the segment of hemophilia has emerged as the fastest growing application as it is a very rare disorder related to bleeding that hampers the normal process of blood clotting. The tremendous growth seen by the market is attributed to the increasing number of cases suffering with hemophilia all over the world especially in the underdeveloped and developed countries.
Or data which was published by world federation of hemophilia around 2020 stated that there are approximately 209, 614 people who are suffering with this disease residing in around 120 countries all over the world. Among these diseases the most prevalent type of hemophilia is hemophilia A. the huge number of patients that exist in the society suffering with this severe disease has a significant impact on the growth of the plasma derived therapy market as it is proved to be and effective treatment procedure which how is the capacity to achieve good results over the period of time.
Why North America region is emerging in the plasma derived therapy market?
North America plasma derived therapy market held over 53% business share in 2021 and is projected to experience remarkable growth during the foreseeable future. Favourable government initiatives and expanding coverage of plasma collection centres by leading market players will offer growth opportunities to the market. Furthermore, increasing awareness about plasma derived therapies among blood donors, and favourable initiatives undertaken by major market players to stimulate blood donation in the region will accelerate the regional revenue growth.
Some of the prominent players in the Plasma Derived Therapy Market include:
- CSL Behring
- Takeda Pharmaceutical Company Limited
- BPL
- ADMA Biologics
- Biotest AG
- Octapharma
- Grifols
- Kamada Pharmaceuticals
- SK Plasma
- SA
- Kedrion
- Pfizer
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Plasma Derived Therapy market
By Product
- Immunoglobulin
- Coagulation factors
- Albumin
- Others
By Application
- Hemophilia
- Primary immunodeficiency disease
- Idiopathic thrombocytopenic purpura
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Plasma Derived Therapy industry analysis from 2022 to 2030 to identify the prevailing Plasma Derived Therapy industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global Plasma Derived Therapy industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Plasma Derived Therapy industry trends, key players, market segments, application areas, and market growth strategies.
Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6947
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
Blog: https://qyresearchmedical.com/
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.